Sign In
Buy CAPR
$3.85
-0.240 (-5.87%)
At Close: Aug 10, 2026
LOS ANGELES, July 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf
BENSALEM, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith announces a continuing investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NAS
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC
01:52pm, Thursday, 30'th Jul 2026
ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securiti
/PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. The
Leading securities law firm [url="]Bleichmar Fonti and Auld LLP[/url] announces an investigation into Capricor Therapeutics, Inc. (NASDAQ: CAPR) for potential secu
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (
NEW YORK--(BUSINESS WIRE)---- $CAPR #BFA--Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law.
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
10:55am, Thursday, 30'th Jul 2026
SAN DIEGO--(BUSINESS WIRE)-- #CAPR--Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and direct
CAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor
10:24am, Thursday, 30'th Jul 2026
/PRNewswire/ -- FDA staff briefing documents released on July 27, 2026 sent Capricor (NASDAQ: CAPR) shares down 60% to 70% after reviewers raised significant
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
09:30am, Thursday, 30'th Jul 2026
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation
08:53am, Thursday, 30'th Jul 2026
PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (N
Capricor plummets after FDA panel votes against Duchenne heart disease therapy
08:06am, Thursday, 30'th Jul 2026
Shares of Capricor Therapeutics fell nearly 60% in premarket trading on Thursday after the U.S. FDA's panel of experts voted against the effectiveness data of its cell therapy for a heart condition
Rosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR
04:00am, Thursday, 30'th Jul 2026
Rosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR PR N
Rosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR
03:58am, Thursday, 30'th Jul 2026
NEW YORK, July 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therape
SAN FRANCISCO, July 29, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. The nationa
